Short-term outcomes of gastrectomy after neoadjuvant chemotherapy for clinical stage III gastric cancer: propensity score-matched analysis of a multi-institutional database

Umeda, Shinichi; Kanda, Mitsuro; Nakanishi, Koki; Ito, Seiji; Mochizuki, Yoshinari; Teramoto, Hitoshi; Ishigure, Kiyoshi; Murai, Toshifumi; Asada, Takahiro; Ishiyama, Akiharu; Matsushita, Hidenobu; Shimizu, Dai; Kobayashi, Daisuke; Tanaka, Chie; Fujiwara, Michitaka; Murotani, Kenta; Kodera, Yasuhiro

doi:10.1007/s00595-020-02179-0

Cited by 7 publications

(26 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Six studies compared the number of lymph node dissection in both groups, and the random-effects model was chosen for relatively moderate heterogeneity ( P = 0.06, I 2 = 53%) [22,29,30,35,37,38] . There was no obvious publication bias according to the funnel plot (Egger test, t = −0.46, P = 0.670; Begg test, z c = 0.00, P = 1.000) [Supplementary Figure 1C, http://links.lww.com/CM9/A641].…”

Section: Resultsmentioning

confidence: 99%

“…Sixteen studies provided effective data for the incidence of anastomotic leakage after gastrectomy, including 1027 in the NACS group and 1540 in the SA group, and a fixed-effects model was applied due to undetected heterogeneity ( P = 0.98, I 2 = 0%) [22–27,29–35,37–39] . The funnel plot suggested no evidence of publication bias (Egger test, t = 0.97, P = 0.100; Begg test, z c = −0.25, P = 0.810) [Supplementary Figure 1K, http://links.lww.com/CM9/A641].…”

Section: Resultsmentioning

confidence: 99%

“…Data from 14 studies, which reported total complications after, were extracted, including 1085 patients in the NACS group and 1576 in the SA group. [22,23,[25][26][27]29,[33][34][35][36][37][38][39][40] A moderate heterogeneity was detected (P = 0.120, ). [10,22,23,25,27,29,30,[32][33][34][35][37][38][39][40] A fixed-effects model was used as a result of undetected heterogeneity (P = 0.780, I 2 = 0%).…”

Section: Total Complicationsmentioning

confidence: 91%

“…Six studies compared the number of lymph node dissection in both groups, and the random-effects model was chosen for relatively moderate heterogeneity (P = 0.06, I 2 = 53%). [22,29,30,35,37,38] There was no obvious publication bias according to the funnel plot (…”

Section: Number Of Harvested Lymph Nodesmentioning

confidence: 97%

“…In seven studies reporting the operation time, a fixed-effects model analysis (P = 0.580, I 2 = 0%) was applied due to the absence of heterogeneity. [29,30,33,[35][36][37][38] The funnel plot suggested there was no publication bias (Egger test, t = À0.21, P = 0.840; Begg test, z c = 0.30, P = 0.760) [Supplementary Figure 1B, http://links.lww.com/CM9/ A641]. The results showed that the operation time in the NACS group was significantly longer than that in the SA group (WMD = 14.27, 95% CI: 6.20-22.34, P < 0.0001).…”

Section: Operation Timementioning

confidence: 99%

See 4 more Smart Citations

Comparison of neoadjuvant chemotherapy followed by surgery vs. surgery alone for locally advanced gastric cancer: a meta-analysis

Wang

Fan

et al. 2021

Chinese Medical Journal

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Total Complicationsmentioning

confidence: 91%

Section: Number Of Harvested Lymph Nodesmentioning

confidence: 97%

Section: Operation Timementioning

confidence: 99%

See 3 more Smart Citations

Comparison of neoadjuvant chemotherapy followed by surgery vs. surgery alone for locally advanced gastric cancer: a meta-analysis

Wang

Fan

et al. 2021

Chinese Medical Journal

View full text Add to dashboard Cite

show abstract

Effectiveness of neoadjuvant chemotherapy with a docetaxel, cisplatin, and S-1 (DCS) regimen for T4b gastric cancer

Long,

Thong,

Dat

et al. 2024

World J Surg Onc

View full text Add to dashboard Cite

Anastomotic Leakage after Gastrectomy for Gastric Cancer

Seicean,

Puscasu,

Gheorghiu

et al. 2023

JGLD

View full text Add to dashboard Cite

Anastomotic leakage (AL) constitutes a prominent cause of significant morbidity following gastrectomy for gastric cancer. The manifestation of AL typically occurs within 7 to 10 days post-surgery, with reported incidence rates of 5.8-6.7% for open gastrectomy and 3.3-4.1% for laparoscopic gastrectomy. Various predisposing risk factors have been identified, including the individual nutritional status (excluding obesity) and preoperative corticotherapy. Interestingly, the administration of neoadjuvant therapies appears to reduce the AL occurrence. In the context of distal gastrectomies, the rates of AL are comparable between laparoscopic, robotic, and open approaches. The total gastrectomies have higher AL rate compared to distal gastrectomies, which are considered the preferred approach. Prophylactic drainage measures have not demonstrated efficacy in preventing AL. As for postoperative management, conservative treatment is indicated for patients presenting with mild clinical symptoms and increased inflammatory blood tests. This approach involves fasting, enteral or parenteral nutrition, administration of antibiotics, and percutaneous drainage. For small AL, endoscopic therapies such as stents, vacuum therapy, clips, suturing devices, and injections are appropriate treatment options. In cases of high-volume fistulas, severe sepsis or failure of previous therapies, surgical reoperation becomes the ultimate solution.

show abstract

Short-term outcomes of gastrectomy after neoadjuvant chemotherapy for clinical stage III gastric cancer: propensity score-matched analysis of a multi-institutional database

Cited by 7 publications

References 20 publications

Comparison of neoadjuvant chemotherapy followed by surgery vs. surgery alone for locally advanced gastric cancer: a meta-analysis

Comparison of neoadjuvant chemotherapy followed by surgery vs. surgery alone for locally advanced gastric cancer: a meta-analysis

Effectiveness of neoadjuvant chemotherapy with a docetaxel, cisplatin, and S-1 (DCS) regimen for T4b gastric cancer

Anastomotic Leakage after Gastrectomy for Gastric Cancer

Contact Info

Product

Resources

About